Skip to content

Health— page 34

health

Merck raises 2026 profit guidance, beats quarterly estimates

By Ludwig Burger, Patricia Weiss and Ozan Ergenay FRANKFURT, Aug 6 (Reuters) – Germany’s Merck KGaA raised its 2026 core profit guidance and beat quarterly expectations on Thursday, helped by continued strong demand for semiconductor materials and drug production supplies. The diversified family-con

· SRN Health
Merck raises 2026 profit guidance, beats quarterly estimates
health

US FDA approves first mRNA flu shot from Moderna

Aug 5 (Reuters) – The U.S. Food and Drug Administration has approved Moderna’s flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for seasonal flu. The shot, mFlusiva, was given a ​traditional approval for adults aged

· SRN Health
US FDA approves first mRNA flu shot from Moderna
health

Solventum to hive off healthcare software business, raises profit forecast

Aug 5 (Reuters) – Solventum, one of the largest providers of hospital consumables and sterilization devices, said on Wednesday it is planning to separate its health information systems business as part of its ongoing turnaround strategy. The company also raised its full-year forecast for organic sal

· SRN Health
health

US FDA approves Takeda’s sleep disorder pill

Aug 5 (Reuters) – The U.S. Food and Drug Administration approved Takeda Pharmaceuticals’ oral drug for narcolepsy, the health regulator said on Wednesday, backing the first treatment that targets all the symptoms of the rare sleep disorder. Here are more details: • Narcolepsy type 1 is a rare sleep

· SRN Health
US FDA approves Takeda’s sleep disorder pill
health

McKesson raises annual profit forecast on strong growth in specialty drug business

Aug 5 (Reuters) – Drug distributor McKesson on Wednesday raised its annual profit forecast after beating first-quarter earnings estimates, on strength in its oncology and specialty drug businesses. The company now expects fiscal 2027 adjusted profit to be in the range of $44.20 to $45 per share, fro

· SRN Health
health

MetLife profit rises on underwriting strength, volume growth

Aug 5 (Reuters) – Life insurer MetLife posted a jump in second-quarter adjusted profit on Wednesday, powered by strong underwriting and broad volume growth, with standout results in Asia and Latin America. The industry has continued to benefit from resilient demand, robust sales growth and disciplin

· SRN Health
MetLife profit rises on underwriting strength, volume growth
health

Explainer-Why Congo’s Ebola outbreak is spreading faster than previous epidemics

By Clement Bonnerot and Jessica Donati DAKAR, Aug 5 (Reuters) – The Ebola epidemic in Democratic Republic of Congo is on track to surpass 4,000 cases this week and has been described as the fastest spreading on record since it was officially declared in May. It is already the world’s second-largest

· SRN Health
Explainer-Why Congo’s Ebola outbreak is spreading faster than previous epidemics
health

US will nearly double financial commitment to Ebola response

By Aaron Ross Aug 5 (Reuters) – The U.S. State Department on Wednesday nearly doubled its financial commitment to the Ebola response in eastern Democratic Republic of Congo, announcing plans to provide an additional $242 million to combat the second-largest outbreak of the disease in history. State

· SRN Health
US will nearly double financial commitment to Ebola response
health

Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case

STOCKHOLM, Aug 5 (Reuters) – Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie from a district court in the Netherlands in a patent infringement case involving a compounded semaglutide nasal spray. Semaglutide is the active ingredient in Novo Nordisk

· SRN Health
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case
health

Gene-edited beagles may offer a future option for people with dog allergies

NEW YORK (AP) — Matt Walker couldn’t pet a dog without sneezing — until he and other scientists used a gene editing technique to produce a hypoallergenic beagle named Bailey. Now, he can feed Bailey spoons of peanut butter while she lies on his lap and play fetch with her in Central Park. His allerg

· SRN Health
Gene-edited beagles may offer a future option for people with dog allergies
health

Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall

By Kunal Das Aug 5 (Reuters) – Insulet lowered its annual sales growth forecast on Wednesday, pointing to a softer second half of 2026 particularly for U.S. sales of its Omnipod insulin pumps, sending shares of the company down nearly 21%. • CEO Ashley McEvoy in a call with analysts said Insulet saw

· SRN Health
health

Charles River lifts profit forecast on improving biotech demand

Aug 5 (Reuters) – Charles River Laboratories raised its annual profit forecast on Wednesday after the contract drug developer beat quarterly profit and revenue estimates on stronger demand for its drug discovery and development services from biotechs. Shares of the company were up more than 8% at $2

· SRN Health
health

Cencora lifts annual profit view on strong demand for specialty medicines

Aug 5 (Reuters) – U.S. drug distributor Cencora raised its annual adjusted profit forecast on Wednesday after quarterly results beat Wall Street expectations, driven by strong demand for specialty medicines. Here are the details: • The company has been sharpening its focus on drug distribution, offl

· SRN Health
health

AI finds previously undetected health risks during sleep studies

By Nancy Lapid Aug 5 (Reuters) – We also report on another promising experimental non-opioid pain drug for use following surgery. AI HELPS FIND UNTAPPED HEALTH PREDICTORS IN SLEEP STUDIES Analyzing routine sleep study data with artificial intelligence reveals a wealth of biomarkers predictive of a m

· SRN Health
AI finds previously undetected health risks during sleep studies
health

Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) – Eli Lilly and Co posted better-than-expected quarterly results and raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs, sending its shares up 5% in premarket tradi

· SRN Health
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth
health

CVS raises annual profit forecast on improved drug revenue

By Amina Niasse NEW YORK, Aug 5 (Reuters) – CVS Health on Wednesday raised its annual profit forecast to reflect a better-than-expected second quarter marked by a more profitable mix of drugs in its pharmacy business and bonus payments for its highly rated government health plans. Shares of the comp

· SRN Health
CVS raises annual profit forecast on improved drug revenue
health

WHO chief visits Congo to support Ebola efforts as some workers strike over pay

KINSHASA, Congo (AP) — The head of the World Health Organization arrived in Congo was in Congo on Wednesday as aid workers said the world’s fastest-growing Ebola outbreak is spreading at an “alarming” rate and some health workers are striking over lack of pay. WHO Director-General Tedros Adhanom Ghe

· SRN Health
WHO chief visits Congo to support Ebola efforts as some workers strike over pay
health

Nepal’s Gandaki province legalizes medical cannabis farming and use

KATHMANDU, Nepal (AP) — A provincial government in Nepal has legalized farming and use of marijuana for medical use despite a national ban. The bill went into effect Monday after it was endorsed by the chief of Gandaki province and allows the farming and medical use of cannabis, said Prabin Poudyal,

· SRN Health
Nepal’s Gandaki province legalizes medical cannabis farming and use
health

Sandoz gains on strong biosimilar growth, touts ‘golden decade’

By Marleen Kaesebier ZURICH, Aug 5 (Reuters) – Swiss generic drug maker Sandoz reported a 9% jump in second-quarter net sales on Wednesday, driven by strong growth in biosimilars as patents expire for popular medicines, boosting the shares. Net sales amounted to $3.01 billion, compared with the $2.9

· SRN Health
health

DaVita flags lower revenue per treatment, reaffirms annual forecast

Aug 4 (Reuters) – DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining enrollments for dialysis treatments as patients dropped out of Obamacare plans following the end of pandemic-era subsidies. Shares of the company, which maintained its annual profit fore

· SRN Health
health

Amgen second-quarter sales rise 9%, profit tops Street view

By Deena Beasley Aug 3 (Reuters) – Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop experimental weight-loss drug MariTide. The California-based biotech said

· SRN Health
Amgen second-quarter sales rise 9%, profit tops Street view